Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)

NCT00684099 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Docetaxel
DRUG: Pemetrexed

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]